Background
Norovirus (NoV) is the most common cause of non-bacterial acute gastroenteritis (AGE) in all age groups worldwide [
1]. Transmission of NoV is mainly via fecally contaminated food or water, by direct contact with patients or vomited virus, and subsequently by contact with contaminated environmental surfaces [
2]. Clinical infection with NoV generally has an incubation time of 12 to 48 h, with nausea, vomiting, watery diarrhea, and abdominal pain [
3].
NoV has a diameter of ~38 nm and belongs to a category of small non-enveloped icosahedral viruses in the Caliciviridae family. The genome of NoV consists of a ~7.5-kb positive sense, single-stranded RNA with three open reading frames (ORF1-ORF3) [
4]. Genetically, NoV has been classified into six genogroups (I–VI) that are further subdivided into over 40 genotypes [
5]. Genogroups I, II, and IV have been found to infect humans, whereas genogroup III infects bovines, and genogroup V has been isolated from mice. The sub-genogroup GII.4 virus accounts for most reported cases, and has been identified as the predominant genotype globally; new GII.4 variants emerge every 2–3 years [
6,
7].
Over the past 7 years, the GII.4 genotype, including GII.4 variants 2006b, New Orleans 2009, and Sydney 2012, has been predominant in Huzhou [
8,
9]. Although various genotypes have been found among genogroups I and II, including GI.P2/GI.2, GI.P3/GI.3, GI.P4/GI.4, GII.P12/GII.3, GII.P7/GII.6, GII.P16/GII.13, and GII.Pg, none has ever replaced the GII.4 genotype.
In the winter of 2014–2015, a novel variant of NoV GII.17 emerged and became predominant in Huzhou, and steadily replaced the previously circulating GII.4 Sydney 2012 strain [
10]. At the same time, GII.17 emerged and became predominant in the United States [
11], Europe [
12], and other places in Asia [
13‐
16].
Did GII.17 appear in Huzhou temporarily, or did it replace GII.4 forever? Here, we report epidemiological patterns and genetic characteristics of NoV after the appearance of GII.17 in Huzhou City, Zhejiang, China.
Discussion
In this study, we determined the levels of NoV activity in sporadic AGE from January to December 2015 in Huzhou, China. The overall prevalence of NoV infection was 26.3% (196/746). Of the 196 NoV-positive specimens, 117 were identified as NoV GII, 4 belonged to NoV GI, and 1 was a combined NoV GI and GII infection. In total, 117 viruses were sequenced, and 88 (75.21%) belonged to a novel GII.P17/GII.17 genotype. In our previous study [
10], We reported the emergence and predominance of norovirus GII.17 in the same hospital from March, 2014 to February 2015. There were overlapping of using the same set of specimens of January and February 2015 between the two studies. NoV infection was detected throughout the year. The circulation peak of NoV occurred during the 2014–2015 winter–spring period.
Generally, young children (aged <5 years) and older adults (aged >60 years) are the at-risk groups for more severe NoV gastroenteritis, partly due to immature and waning immunity, respectively [
23]. Our previous research found that children (≤10 years) and elderly individuals (>60 years) were more likely to be infected with GII.4 [
10].
In contrast, GII.17 seemed more likely to infect people aged 16–60 years, previously considered the least vulnerable population. Chan MC [
24] recently reported that the median (IQR) age of GII.17 (
n =128) cases was significantly older than that of GII.4 (
n =163) cases (49 (9–75) versus 1 (1–8) years, the proportion of older children and young adults (aged 5–65 years) and older adults (aged > 65 years) in GII.17 cases were higher than in GII.4 cases (47.7% vs 19.0%,36.7% vs 11.0% respectively). Adults aged 16–60 years are generally regarded as non-compromised, and thus unlikely to develop severe NoV gastroenteritis that requires medical attention. Why the adults seem more susceptible to the novel GII.P17/GII.17 virus need to be further studied.
Generally, NoV activity peaks in the winter–spring period, but we found no significant increase in the winter of 2015 compared to the summer and autumn of 2015. This may be because, after several months of exposure to NoV GII.17, the population had acquired immunity against GII.17, and the previously circulating GII.4 Sydney 2012 strain was still at low levels of activity.
Over the past two decades, NoV GII.4 variants have been responsible for the majority of both outbreaks and sporadic cases of AGE [
25]. GII.4 variants have emerged every 2–3 years, and the new variants then replaced the old ones as the predominant variant. The emergence of novel GII.4 variants has caused at least six pandemics of NoV-associated acute gastroenteritis: US 95/96 (1995–1996), Farmington Hills (2002–2003), Hunter (2004–2005), Den-Haag 2006b (2006–2007), New Orleans 2009 (2009–2010), and most recently, GII.4 Sydney 2012 (2012–2013) [
26‐
31]. The GII.4 Sydney-2012 variant (a recombination of strains GII.Pe/GII.4) was first identified in Australia in March 2012. Subsequently, various countries worldwide reported higher incidences of NoV outbreaks or illnesses during the winter of 2012–2013; most were caused by the GII.4 Sydney 2012 variant [
31‐
33]. The success of GII.4 viruses is due to their evolution through the accumulation of mutations into drift variants that escape immunity from previous exposure [
34], intra-genotype recombination of contemporary GII.4 noroviruses that foster the emergence of novel GII.4 variants [
35], and alterations in binding properties [
36].
In the Huzhou area, the GII.4 Sydney 2012 variant was first identified in November 2012, and became the predominant GII.4 variant soon thereafter. This variant caused several outbreaks in the Huzhou area between 2012 and 2014 [
8]. Between October 2014 and June 2015, the GII.4 Sydney 2012 variant was replaced by a novel GII.P17/GII.17 variant, and the detection rate decreased greatly. In the winter of 2015, the GII.4 Sydney 2012 variant re-emerged in Huzhou. Further investigations are needed to elucidate the changing epidemiological trends of NoVs in Huzhou.
Some other genotypes, such as GII.3, GII.6, and GII.13, were also detected in Huzhou. However, none of these non-GII.4 genotypes ever replaced the GII.4 genotypes’ dominance. The novel GII.P17/GII.17 variant was first detected in October 2014 in Huzhou, and caused an increasing number of sporadic cases. During the 2014–2015 season, it became predominant, replacing the GII.4 Sydney variant from January 2015 [
10]. This result is consistent with studies from other regions of China and in other countries [
13‐
16]. This was the first time that a non-GII.4 genotype replaced the GII.4 variants as the predominant strain in Huzhou.
The GII.17 genotype has been circulating in the human population for several decades [
37]. In Africa, Asia, North America, and South America, GII.17 has been detected sporadically [
38‐
42]. According to CaliciNet, there were four reported GII.17 outbreaks between 2009 and 2013 in the United States [
43]. During this period, Denmark and South Africa reported sporadic GII.17 cases on Noronet [
44]. Kiulia reported that the NoV GII.17 virus accounted for 76% of all detected NoV strains in rivers in rural and urban areas in Kenya between 2012 and 2013 [
45].
In the 2014–2015 season, a NoV genotype GII.P17/GII.17 variant emerged and caused outbreaks in multiple cities in Guangdong Province, China [
14]. During that winter, 23 outbreaks of NoV AGE occurred; 16 were related to a new GII.17 variant in Jiangsu, China [
15]. In other parts of Asia, such as Hong Kong [
24] and Taiwan, the novel GII.17 also became predominant at about the same time [
46]; similarly, in other countries, such as Japan and the United States, the novel GII.17 variant also caused an increase in the number of cases during the 2014–2015 season [
11,
13].
However, not all NoV outbreaks or sporadic AGE cases are genotyped beyond the GI and GII classification, so the new GII.17 may have been more common than we know. Indeed, most previously available GII.17 sequences included only the 5’-end of VP1 (C region), and very few sequences covered ORF1 or ORF2 [
22]. Viruses with a GII.17 VP1 genotype contain an ORF1 genotype with the GII.P13, GII.P16, GII.P3, or GII.P4 genotype [
41,
47‐
49]. These previous GII.17 viruses did not cause an increase in NoV activity. Once the new GII.P17 RdRp gene combined with the GII.17 ORF1 gene, the new GII.P17/GII.17 then steadily replaced GII.Pe/GII.4 (GII.4 Sydney 2012) as the predominant NoV in circulation worldwide. The acquisition of the novel ORF1 may explain the sudden emergence and the widespread ability of the new GII.P17/GII.17 variant. Sequence comparisons of GII.17 variants detected in October 2014 in Huzhou showed an RNA-dependent RNA polymerase (RdRp) gene cluster with GII.P13 viruses that had not been detected before [
11]. Thus, in previous studies, we assigned the new viruses as GII.P13/GII.17 [
10]. This variant was ultimately assigned to the RdRp genotype, GII.P17 [
13]. Thus, the strains predominant in 2014–2015 in Huzhou were in fact GII.P17/GII.17 viruses.